ストックスクリーナーアプリを入手
1.60
1.91%
0.03
アフターアワーズ：
1.59
-0.01
-0.63%
前日終値:
$1.57
開ける：
$1.52
24時間の取引高:
4.33M
Relative Volume:
0.64
時価総額：
$483.20M
収益：
$160.01M
当期純損益:
$-546.38M
株価収益率:
-0.8719
EPS:
-1.835
ネットキャッシュフロー:
$-118.92M
1週間 パフォーマンス:
+8.84%
1か月 パフォーマンス:
+20.30%
6か月 パフォーマンス:
-8.05%
1年 パフォーマンス:
+25.98%
1日の値動き範囲:
$1.52
$1.635
1週間の範囲:
$1.31
$1.635
52週間の値動き範囲:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.60 | 474.14M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance Australia
PacBio, Covaris develop workflow for FFPE tissue sequencing By Investing.com - Investing.com Canada
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples - marketscreener.com
Archived tumor samples gain long-read DNA workflow with 60% phasing - Stock Titan
Pacific Biosciences of California fosters connections and momentum at PacBioPRISM event - Traders Union
PACB Maintained by Barclays -- Price Target Lowered to $1.00 - GuruFocus
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1 - Moomoo
Pacific Biosciences (PACB) Garnering Attention Amid Involvement in Trillion Gene Atlas Program - Insider Monkey
Pacific Biosciences of California introduces expanded long-read assay to streamline clinical workflows - Traders Union
Market Pulse: Can Pacific Biosciences of California Inc reach all time highs this yearQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - TradingView — Track All Markets
How The PacBio (PACB) Story Is Shifting Between Long Term Potential And Near Term Risks - Yahoo Finance
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California unveils step-by-step HiFi sequencing process leveraging Revio and Vega platforms - Traders Union
Director Christopher Gibson receives options and RSUs at Pacific Biosciences (PACB) - Stock Titan
Pacific Biosciences of California unveils SPRQ-Nx chemistry to streamline cancer testing workflows - Traders Union
Pacific Biosciences of California Inc (MEX:PACB) Stock Price, Trades & News - GuruFocus
Ontario-Based DNAstack Leads Sovereign AI for Genomics and Health with Goal of Making Canadians Healthier and Reducing Strain on our Healthcare System - marketscreener.com
PacBio HiFi WGS resolves hidden disease-linked structural variants in diverse populations - Traders Union
Fundamentals Check: Will Pacific Biosciences of California Inc outperform tech stocksWeekly Trend Summary & Reliable Entry Point Alerts - baoquankhu1.vn
MEX:PACB EV-to-OCF: -7.12 | Modestly Undervalued - GuruFocus
Pacific Biosciences of California (PACB) Outperforms the Market: The Reasons Explained - Bitget
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why - Yahoo Finance
Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications - GlobeNewswire Inc.
Pacific Biosciences of California launches HiFi sequencing workshop at AACR26 for cancer genomics - Traders Union
Pacific Biosciences of California Inc (P09.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Pacific Biosciences of California traces DNA sequencing evolution from Sanger to HiFi platforms - Traders Union
Pacific Biosciences (NASDAQ: PACB) officer sells 88,185 shares for taxes - Stock Titan
Pacific Biosciences of California Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView — Track All Markets
Pacific Biosciences of California expands HiFi WGS and targeted panels to detect hidden cancer variants - Traders Union
Pacific Biosciences of California, Inc. (PACB) latest stock news and headlines - Yahoo Finance Singapore
Trade Report: How does Pacific Biosciences of California Inc compare to its peersMarket Growth Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
[144] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing - Stock Titan
Here’s Why PacBio Shares Deserve a Place in Your Portfolio Today - Bitget
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Yahoo Finance
PACB PE Ratio & Valuation, Is PACB Overvalued - Intellectia AI
Pacific Biosciences of California unveils oncology workflow solutions at industry event - Traders Union
Returns Recap: Will Pacific Biosciences of California Inc outperform during market rallies2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024 - 富途牛牛
Pacific Biosciences Stock: Long-Read Sequencing Leader Faces Evolving Genomics Landscape - AD HOC NEWS
Stock Report: Can Pacific Biosciences of California Inc reach all time highs this year2026 Final Week & Real-Time Stock Movement Alerts - baoquankhu1.vn
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note - finance.yahoo.com
Vanguard amendment shows 0 PACB shares after realignment (PACB) - Stock Titan
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider - Bitget
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - MSN
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):